These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 19424581

  • 1. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
    Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Blackie R, Schatzlein A, Jodrell D, Bissett D, Calvert H, Lind M, Robbins A, Burtles S, Duncan R, Cassidy J.
    Int J Oncol; 2009 Jun; 34(6):1629-36. PubMed ID: 19424581
    [Abstract] [Full Text] [Related]

  • 2. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
    Bakker M, Droz JP, Hanauske AR, Verweij J, van Oosterom AT, Groen HJ, Pacciarini MA, Domenigoni L, van Weissenbruch F, Pianezzola E, de Vries EG.
    Br J Cancer; 1998 Jun; 77(1):139-46. PubMed ID: 9459159
    [Abstract] [Full Text] [Related]

  • 3. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
    Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J.
    Clin Cancer Res; 1999 Jan; 5(1):83-94. PubMed ID: 9918206
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study.
    Schöffski P, Besse B, Gauler T, de Jonge MJ, Scambia G, Santoro A, Davite C, Jannuzzo MG, Petroccione A, Delord JP.
    Ann Oncol; 2015 Mar; 26(3):598-607. PubMed ID: 25488684
    [Abstract] [Full Text] [Related]

  • 5. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
    Tomalova B, Sirova M, Rossmann P, Pola R, Strohalm J, Chytil P, Cerny V, Tomala J, Kabesova M, Rihova B, Ulbrich K, Etrych T, Kovar M.
    J Control Release; 2016 Feb 10; 223():1-10. PubMed ID: 26708020
    [Abstract] [Full Text] [Related]

  • 6. [Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline].
    Tabata M, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Nagamine D, Shinagawa K, Fukutani H, Hirano A, Mizunuma N.
    Gan To Kagaku Ryoho; 1989 Jul 10; 16(7):2361-6. PubMed ID: 2546503
    [Abstract] [Full Text] [Related]

  • 7. Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma.
    Pimm MV, Perkins AC, Strohalm J, Ulbrich K, Duncan R.
    J Drug Target; 1996 Jul 10; 3(5):385-90. PubMed ID: 8866657
    [Abstract] [Full Text] [Related]

  • 8. HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.
    Etrych T, Subr V, Strohalm J, Sírová M, Ríhová B, Ulbrich K.
    J Control Release; 2012 Dec 28; 164(3):346-54. PubMed ID: 22759979
    [Abstract] [Full Text] [Related]

  • 9. Prospects for pirarubicin.
    Miller AA, Salewski E.
    Med Pediatr Oncol; 1994 Dec 28; 22(4):261-8. PubMed ID: 8107658
    [No Abstract] [Full Text] [Related]

  • 10. Gamma scintigraphy of the biodistribution of 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma.
    Pimm MV, Perkins AC, Strohalm J, Ulbrich K, Duncan R.
    J Drug Target; 1996 Dec 28; 3(5):375-83. PubMed ID: 8866656
    [Abstract] [Full Text] [Related]

  • 11. Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group.
    Verweij J, Wanders J, Nielsen AL, Pavlidis N, Calabresi F, ten Bokkel Huinink W, Bruntsch U, Piccart M, Franklin H, Kaye SB.
    Ann Oncol; 1994 Apr 28; 5(4):375-6. PubMed ID: 8075039
    [Abstract] [Full Text] [Related]

  • 12. Improvement of anti-tumor abilities on human non-small cell lung carcinoma by micellization and cross-linking of N-(2-hydroxypropyl) methacrylamide copolymers.
    Zhou Z, Xu X, Li L, Huang Y.
    J Drug Target; 2015 Apr 28; 23(9):821-31. PubMed ID: 25830626
    [Abstract] [Full Text] [Related]

  • 13. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
    Schwartsmann G, Mans DR, Menke CH, Xavier N, Caleffi M, Ferreira Filho AF, Schunemann H, Kalakun L, Koya R, Pohlman P, Venegas LF.
    Oncology (Williston Park); 1997 Apr 28; 11(4 Suppl 3):24-9. PubMed ID: 9144687
    [Abstract] [Full Text] [Related]

  • 14. Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.
    Gamucci T, Paridaens R, Heinrich B, Schellens JH, Pavlidis N, Verweij J, Sessa C, Kaye S, Roelvink M, Wanders J, Hanauske A.
    Ann Oncol; 2000 Jul 28; 11(7):793-7. PubMed ID: 10997805
    [Abstract] [Full Text] [Related]

  • 15. Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.
    Palmieri C, Misra V, Januszewski A, Yosef H, Ashford R, Keary I, Davidson N.
    Clin Breast Cancer; 2014 Apr 28; 14(2):85-93. PubMed ID: 24325950
    [Abstract] [Full Text] [Related]

  • 16. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF, Hemmati P, Lehenbauer-Dehm S, Kümmel S, Flath B, Schmid P.
    Clin Breast Cancer; 2016 Dec 28; 16(6):514-519. PubMed ID: 27395417
    [Abstract] [Full Text] [Related]

  • 17. Anthracyclines in non-small-cell lung cancer: do they have a therapeutic role?
    Martoni A, Guaraldi M, Piana E.
    Ann Oncol; 1999 Dec 28; 10 Suppl 5():S19-23. PubMed ID: 10582134
    [Abstract] [Full Text] [Related]

  • 18. Phase II studies of 4'-iodo-4'-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers.
    Sessa C, Calabresi F, Cavalli F, Cerny T, Liati P, Skovsgaard T, Sorio R, Kaye SB.
    Ann Oncol; 1991 Dec 28; 2(10):727-31. PubMed ID: 1666296
    [Abstract] [Full Text] [Related]

  • 19. Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate.
    Duncan R, Sat-Klopsch YN, Burger AM, Bibby MC, Fiebig HH, Sausville EA.
    Cancer Chemother Pharmacol; 2013 Aug 28; 72(2):417-27. PubMed ID: 23797686
    [Abstract] [Full Text] [Related]

  • 20. The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers.
    Rossi A, Torri V, Garassino MC, Porcu L, Galetta D.
    Cancer Treat Rev; 2014 May 28; 40(4):485-94. PubMed ID: 24112813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.